Patents Assigned to Singapore Health Services Pte, Ltd
  • Patent number: 11116635
    Abstract: The present invention relates to a device for cardiac valve repair, the device comprising: at least one upstream anchoring means adapted to anchor to at least one tissue site, the tissue site located upstream with respect to a heart valve of a patient; and a coaptation structure arranged to extend from the upstream anchoring means, the coaptation structure comprising a free end, wherein the coaptation structure is operable to extend across the heart valve and locate the free end downstream from the heart valve and the coaptation structure operable to coapt with at least one heart valve leaflet of the patient's heart to prevent and/or minimize a backflow of blood. The present invention is suitable for the treatment of heart valves using minimally invasive approaches. Additionally, the present invention is directed to a method of implanting a device for cardiac valve repair in a patient's heart.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: September 14, 2021
    Assignee: SINGAPORE HEALTH SERVICES PTE LTD
    Inventors: Khung Keong Yeo, Nicolas Daniel Marie Foin
  • Patent number: 11084874
    Abstract: Provided are antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 10, 2021
    Assignees: Singapore Health Services PTE LTD., National University of Singapore, Boehringer Ingelheim International GmbH
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Patent number: 11084878
    Abstract: Provided are antigen-binding molecules capable of binding to IL-11R?, and methods of medical treatment and prophylaxis using the same.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 10, 2021
    Assignees: National University of Singapore, Singapore Health Services PTE LTD., Boehringer Ingelheim International GmbH
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Patent number: 11078269
    Abstract: IL-11R? antibodies are disclosed. Also disclosed are compositions comprising the IL-11R? antibodies, and methods using the IL-11R? antibodies.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 3, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Patent number: 11078268
    Abstract: IL-11 antibodies are disclosed. Also disclosed are compositions comprising the IL-11 antibodies, and methods using the IL-11 antibodies.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 3, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Publication number: 20210230266
    Abstract: Provided are antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 29, 2021
    Applicants: Singapore Health Services PTE LTD., National University of Singapore, Boehringer Ingelheim International GmbH
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Publication number: 20210188962
    Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
    Type: Application
    Filed: December 2, 2020
    Publication date: June 24, 2021
    Applicants: Singapore Health Services PTE LTD., National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Publication number: 20210177940
    Abstract: Methods of treating and preventing metabolic disease through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.
    Type: Application
    Filed: May 1, 2020
    Publication date: June 17, 2021
    Applicants: Singapore Health Services PTE LTD., National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer, Brijesh Kumar Singh, Anissa Widjaja
  • Patent number: 11000516
    Abstract: Methods of preventing a disease resulting from a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I); a compound of Formula (I) can be first administered to an asymptomatic human subject followed by subsequent doses administered at least once daily. The methods of the invention can be used to prevent a disease resulting from primary and secondary DENV 1-4 viral infections.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 11, 2021
    Assignees: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Subhash Vasudevan, Geoffrey S. Dow, Satoru Watanabe, Eng Eong Ooi, Jenny Low, Kitti Wing Ki Chan
  • Patent number: 10932946
    Abstract: There is provided a device for insertion into a body cavity, the device includes an insertion member configured to be inserted into the body cavity, an expandable member coupled to the insertion member, the expandable member capable of being expanded to apply pressure onto tissue within the body cavity, a first member configured for storing a first endothermic reactant therein, and a second member configured for storing a second endothermic reactant therein. In particular, the first and second members are configured to, in a state of the device (e.g., compressed state), allow the first and second endothermic reactants to cooperate to effect an endothermic reaction to generate an endothermic product. Furthermore, the expandable member is configured to receive at least one of the first or second endothermic reactant and the endothermic product through a channel within the insertion member. There is also provided a method of fabricating a device for inserting into a body cavity.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: March 2, 2021
    Assignees: Agency for Science, Technology and Research, National University Hospital (Singapore) Pte Ltd, Singapore Health Services Pte Ltd
    Inventors: Prusothman M Sina Raja, Angela Renayanti Dharmawan, Chee Keong Tee, Yao Wang, Sheau Huei Frances Lim, Zhengtao Keith Chong
  • Patent number: 10927169
    Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: February 23, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Patent number: 10925737
    Abstract: Mandible endoprosthesis implant and mandible endoprosthesis implant system and surgical kit comprising the same, the mandible endoprosthesis implant comprising: first end second implant elements which can be coupled in a manner so as to allow a relative pivotal movement therebetween. The present disclosure further provides methods for surgically repairing a mandible.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: February 23, 2021
    Assignee: SINGAPORE HEALTH SERVICES PTE LTD.
    Inventors: Bee Tin Goh, Yuchun Liu, Nattharee Chanchareonsook, Wei Yang Edwin Liu
  • Publication number: 20210045657
    Abstract: A device and method for measuring respiratory air flow of a subject are provided. The device includes a hollow member having a proximal end, a distal end and a flow passage formed between the proximal and distal ends. The proximal end is configured to be received in a mouth of a subject. A flow sensor, such as thermal mass flow sensor, is disposed in the flow passage and configured to sense characteristics of an air flow in the flow passage. A processor is communicatively coupled to the flow sensor and configured to determine, based on an output from the flow sensor, whether the sensed characteristics of the air flow correspond to predetermined parameters.
    Type: Application
    Filed: March 4, 2019
    Publication date: February 18, 2021
    Applicant: Singapore Health Services Pte Ltd
    Inventors: Biju THOMAS, Zhi Qian HEN, Dirk Frans DE KORNE
  • Patent number: 10899832
    Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: January 26, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Patent number: 10894825
    Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: January 19, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Patent number: 10894826
    Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: January 19, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Patent number: 10894827
    Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: January 19, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Patent number: 10889642
    Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: January 12, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Patent number: 10888282
    Abstract: A method of producing an artificial neural network capable of predicting the survivability of a patient, including: storing in an electronic database patient health data comprising a plurality of sets of data, each set having at least one of a first parameter relating to heart rate variability data and a second parameter relating to vital sign data, each set further having a third parameter relating to patient survivability; providing a network of nodes interconnected to form an artificial neural network, the nodes comprising a plurality of artificial neurons, each artificial neuron having at least one input with an associated weight; and training the artificial neural network using the patient health data such that the associated weight of the at least one input of each artificial neuron is adjusted in response to respective first, second and third parameters of different sets of data from the patient health data.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: January 12, 2021
    Assignees: SINGAPORE HEALTH SERVICES PTE LTD., NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Marcus Eng Hock Ong, Zhiping Lin, Wee Ser, Guangbin Huang
  • Publication number: 20200408756
    Abstract: Methods and kits for evaluating a clinical outcome of an autoimmune disease, specifically disease flare e.g. if the subject stops taking the biologic disease modifying anti-rheumatic drug (DMARD), by comparing biomarkers of CD45RA, TNF-alpha and/or CXCR5 from CD3+CD4+ T cell population are disclosed. In a specific embodiment, the ratio of first subset of CD3+CD4+CD45RA?TNFA+ (memory) T cells to a second subset comprising CD3+CD4+CD45RA+TNFA+ (naïve) T cell is determined, wherein an increase in the ratio indicates a disease flare state of juvenile idiopathic arthritis (JIA). In another embodiment, enrichment of CD45RA?CR5+ subset among the T cell population indicates likelihood of flare state in JIA via memory persistence enhancement through B cell interaction. In other embodiments, additional markers including IL-6, CCR6, CD152 and PD1 are also determined, and the enrichment of CD45RA-TNFA+IL-6+ subset among the T cell population indicates a likelihood of amplification of the autoimmune disease.
    Type: Application
    Filed: June 11, 2018
    Publication date: December 31, 2020
    Applicant: SINGAPORE HEALTH SERVICES PTE. LTD.
    Inventors: Salvatore ALBANI, Jing Yao LEONG